X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125557
https://www.prnewswire.com/news-releases/fda-grants-full-approval-for-blincyto-blinatumomab-to-treat-minimal-residual-disease-positive-b-cell-precursor-acute-lymphoblastic-leukemia-301856128.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125557
https://endpts.com/wuxi-inks-1-5b-gsk-pact-a-big-biobuck-bet-but-a-blip-in-billions-lost-from-us-unverified-list/
https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-consolidation-chemotherapy-significantly-improves-survival-in-adult-patients-with-measurable-residual-disease-negative-b-lineage-acute-lymphoblastic-leukemia-b-all-301702114.html
https://www.fiercepharma.com/pharma/amgens-blincyto-looks-expand-leukemia-use-after-9-year-trial
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125557
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125557
https://www.clinicaltrialsarena.com/news/amgen-blincyto-leukaemia-study/
https://www.prnewswire.com/news-releases/blincyto-blinatumomab-demonstrated-significantly-prolonged-event-free-survival-compared-with-consolidation-chemotherapy-in-pediatric-patients-with-relapsed-acute-lymphoblastic-leukemia-301238918.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125557
https://www.amgen.com/media/news-releases/2020/01/amgen-commences-strategic-collaboration-with-beigene-to-expand-oncology-presence-in-china/
https://endpts.com/amgen-takes-a-2-7b-stake-in-beigene-gaining-a-prominent-ally-in-china-to-help-seize-a-leading-role-in-cancer-drug-commercialization-and-development/
https://www.fiercepharma.com/pharma/most-expensive-meds-u-s-topped-by-novartis-and-spark-gene-therapies
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125557
http://www.pharmatimes.com/news/nice_evidence_request_for_blincyto_for_acute_lymphoblastic_leukaemia_1280608
Market Place
Share 
